GamaMabs Pharma develops innovative monoclonal antibodies in cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer.

The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.